BR9712808B1 - unsubstituted indol-3-glyoxylamides, as well as the application, medicament and process for their preparation. - Google Patents

unsubstituted indol-3-glyoxylamides, as well as the application, medicament and process for their preparation.

Info

Publication number
BR9712808B1
BR9712808B1 BRPI9712808-2A BR9712808A BR9712808B1 BR 9712808 B1 BR9712808 B1 BR 9712808B1 BR 9712808 A BR9712808 A BR 9712808A BR 9712808 B1 BR9712808 B1 BR 9712808B1
Authority
BR
Brazil
Prior art keywords
glyoxylamides
medicament
preparation
well
application
Prior art date
Application number
BRPI9712808-2A
Other languages
Portuguese (pt)
Other versions
BR9712808A (en
Inventor
Guillaume Lebaut
Cecilia Menciu
Bernhard Kutscher
Peter Emig
Stefan Szelenyi
Brune Kay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR9712808A publication Critical patent/BR9712808A/en
Publication of BR9712808B1 publication Critical patent/BR9712808B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
BRPI9712808-2A 1996-09-06 1997-08-16 unsubstituted indol-3-glyoxylamides, as well as the application, medicament and process for their preparation. BR9712808B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19636150A DE19636150A1 (en) 1996-09-06 1996-09-06 N-substituted indole-3-glyoxylamides with antiasthmatic, antiallergic and immunosuppressive / immunomodulating effects
PCT/EP1997/004474 WO1998009946A1 (en) 1996-09-06 1997-08-16 N-substituted indol-3-glyoxylamid with antiasthmatic, antiallergic and immunosuppressive/immunomodulating effect

Publications (2)

Publication Number Publication Date
BR9712808A BR9712808A (en) 1999-11-23
BR9712808B1 true BR9712808B1 (en) 2009-05-05

Family

ID=7804772

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9712808-2A BR9712808B1 (en) 1996-09-06 1997-08-16 unsubstituted indol-3-glyoxylamides, as well as the application, medicament and process for their preparation.

Country Status (27)

Country Link
US (4) US6008231A (en)
EP (1) EP0931063B3 (en)
JP (1) JP3296437B2 (en)
KR (1) KR100516321B1 (en)
CN (3) CN100376554C (en)
AR (1) AR008630A1 (en)
AT (1) ATE342889T1 (en)
AU (1) AU726521B2 (en)
BR (1) BR9712808B1 (en)
CA (1) CA2215013C (en)
CZ (1) CZ302301B6 (en)
DE (2) DE19636150A1 (en)
DK (1) DK0931063T5 (en)
ES (1) ES2276433T7 (en)
HK (3) HK1021641A1 (en)
HU (1) HU227797B1 (en)
IL (1) IL127798A (en)
NO (2) NO314725B3 (en)
NZ (1) NZ334476A (en)
PT (1) PT931063E (en)
RU (1) RU2237661C2 (en)
SK (1) SK285618B6 (en)
TR (1) TR199900469T2 (en)
TW (1) TW550256B (en)
UA (1) UA60312C2 (en)
WO (1) WO1998009946A1 (en)
ZA (1) ZA977475B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636150A1 (en) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituted indole-3-glyoxylamides with antiasthmatic, antiallergic and immunosuppressive / immunomodulating effects
KR100584650B1 (en) * 1998-03-31 2006-05-30 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 Substituted indolealkanoic acids
DE19814838C2 (en) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylic acid derivatives with anti-tumor effects
CZ302588B6 (en) * 1998-04-02 2011-07-27 Ziopharm Oncology, Inc. Use of N-substituted indole-3-gloxylamide for preparing a medicament
DE19946301A1 (en) 1998-04-02 2001-04-19 Asta Medica Ag Antitumor agents and angiogenesis inhibitors having low neurotoxicity, comprise indole-3-glyoxylamide derivatives, are effective against resistant and metastasis-forming carcinomas
IL138847A0 (en) 1998-04-28 2001-10-31 Dresden Arzneimittel New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
DE19818964A1 (en) * 1998-04-28 1999-11-04 Dresden Arzneimittel New hydroxy-indole derivatives useful in treatment of degenerative joint disease, viral and parasitic infections, bronchial, dermatological, neurodegenerative and prostate disorders, etc.
DE19917504A1 (en) * 1999-04-17 2000-10-19 Dresden Arzneimittel New hydroxy-indole derivatives, useful in treatment of degenerative joint disease, viral and parasitic infections, bronchial, dermatological, neurodegenerative and prostate disorders, etc.
SI1212089T1 (en) 1999-08-21 2006-08-31 Altana Pharma Ag Synergistic combination of roflumilast and salmeterol
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
DE19962300A1 (en) * 1999-12-23 2001-06-28 Asta Medica Ag New N-benzylindolyl glyoxylic acid derivatives are useful as antitumor agents
DE10022925A1 (en) * 2000-05-11 2001-11-15 Basf Ag New indole-carboxamide or azepino-indole derivatives and analogs, are poly-ADP ribose polymerase inhibitors useful e.g. for treating neurodegenerative disease, ischemia, epilepsy, tumors, sepsis or diabetes mellitus
DE10037310A1 (en) 2000-07-28 2002-02-07 Asta Medica Ag New indole derivatives and their use as medicines
WO2003022280A2 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 3-glyoxlylamideindoles for treating cancer
TWI323658B (en) * 2001-12-06 2010-04-21 Nat Health Research Institutes Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same
KR20050026002A (en) * 2002-07-26 2005-03-14 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 Substituted indolealkanoic acids derivative and formulations containing same for use in treatment of diabetic complications
CN1325490C (en) * 2002-08-01 2007-07-11 埃尔比昂股份公司 Method for producing highly pure hydroxy indolyl glyoxylic acid amides
DE10253426B4 (en) * 2002-11-15 2005-09-22 Elbion Ag Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and methods for their preparation
DE10318611A1 (en) * 2003-04-24 2004-11-11 Elbion Ag 4-, 6- or 7-hydroxyindoles with N-oxide groups and their use as therapeutic agents
DE10318609A1 (en) * 2003-04-24 2004-11-11 Elbion Ag 5-hydroxyindoles with N-oxide groups and their use as therapeutic agents
DE10318610A1 (en) * 2003-04-24 2004-11-11 Elbion Ag 7-azaindoles and their use as therapeutic agents
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
AU2004270733B2 (en) 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
DE102004031538A1 (en) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Presentation form (obtainable by dissolving indibulin in or with a highly concentrated organic acid), useful to orally administer poorly soluble active compound indibulin, comprises a poorly soluble active compound indibulin
US20060110462A1 (en) * 2004-11-08 2006-05-25 Pavlos Papadopoulos Nanoparticulate compositions of tubulin inhibitor compounds
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
EP1848430B1 (en) 2004-12-31 2017-08-02 Dr. Reddy's Laboratories Ltd. Novel benzylamine derivatives as cetp inhibitors
JP2006247963A (en) * 2005-03-09 2006-09-21 Oji Paper Co Ltd Inkjet recording sheet
EP1865949B1 (en) * 2005-03-11 2012-11-14 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CA2607069A1 (en) 2005-04-29 2006-11-09 Tendix Development, Llc Radial impulse engine, pump, and compressor systems, and associated methods of operation
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US7598380B2 (en) * 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
ITMI20051999A1 (en) * 2005-10-21 2007-04-22 Eratech S R L INHALATION FORMULATIONS OF DRUGS IN DRY POWDER FOR ADMINISTRATION AS SUCH OR WITH NEBULIZER AND EQUIPPED WITH HIGH EROGABILITY RESPIRABILITY AND STABILITY
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
CN102772411A (en) 2006-07-05 2012-11-14 奈科明有限责任公司 Combination of HMG-COA reductase inhibitors, such as roflumilast, roflumilast-N-oxide with a phosphodiesterase 4 inhibitor, rosuvastatin, for the treatment of inflammatory pulmonary diseases
CA2660704A1 (en) * 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
WO2008073623A2 (en) * 2006-11-02 2008-06-19 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
EP2091532A1 (en) * 2006-11-28 2009-08-26 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AR084433A1 (en) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc FAAH INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2013024358A2 (en) 2011-08-18 2013-02-21 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
WO2013046045A1 (en) 2011-09-27 2013-04-04 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
CN109000634B (en) * 2018-06-04 2022-06-03 上海智蕙林医疗科技有限公司 Navigation object traveling route reminding method and system

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797258A (en) * 1955-04-11 1958-06-25 Upjohn Co 3-substituted indoles
GB944443A (en) * 1959-09-25 1900-01-01
GB1028812A (en) * 1962-08-28 1966-05-11 Ici Ltd Indole derivatives
GB1089071A (en) * 1964-02-28 1967-11-01 Merck & Co Inc Indole derivatives
US3686213A (en) * 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
FR2689888B1 (en) * 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa NOVEL PERHYDROISOINDOLE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
RU2128169C1 (en) * 1994-04-01 1999-03-27 Эли Лилли Энд Компани 1h-indole-3-glyoxylamides inhibiting -mediated fatty acids releasing, a pharmaceutical composition
DE19636150A1 (en) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituted indole-3-glyoxylamides with antiasthmatic, antiallergic and immunosuppressive / immunomodulating effects
DE19946301A1 (en) * 1998-04-02 2001-04-19 Asta Medica Ag Antitumor agents and angiogenesis inhibitors having low neurotoxicity, comprise indole-3-glyoxylamide derivatives, are effective against resistant and metastasis-forming carcinomas
US7205299B2 (en) * 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect

Also Published As

Publication number Publication date
WO1998009946A1 (en) 1998-03-12
TR199900469T2 (en) 1999-05-21
SK27199A3 (en) 1999-08-06
SK285618B6 (en) 2007-05-03
HK1123280A1 (en) 2009-06-12
NO20030481D0 (en) 2003-01-30
UA60312C2 (en) 2003-10-15
HK1021641A1 (en) 2000-06-23
CN1227542A (en) 1999-09-01
DE19636150A1 (en) 1998-03-12
ZA977475B (en) 1998-02-19
NO991071D0 (en) 1999-03-04
NZ334476A (en) 2000-05-26
US6344467B1 (en) 2002-02-05
AR008630A1 (en) 2000-02-09
EP0931063B3 (en) 2009-04-08
US20020161025A1 (en) 2002-10-31
RU2237661C2 (en) 2004-10-10
AU726521B2 (en) 2000-11-09
CA2215013C (en) 2002-03-05
CN101219985A (en) 2008-07-16
BR9712808A (en) 1999-11-23
AU726521C (en) 1998-03-26
CN101219985B (en) 2011-04-27
ATE342889T1 (en) 2006-11-15
CN100488948C (en) 2009-05-20
ES2276433T7 (en) 2009-11-05
US6008231A (en) 1999-12-28
IL127798A0 (en) 1999-10-28
TW550256B (en) 2003-09-01
CZ302301B6 (en) 2011-02-09
KR20000068495A (en) 2000-11-25
JP2000505098A (en) 2000-04-25
EP0931063A1 (en) 1999-07-28
HK1064379A1 (en) 2005-01-28
CA2215013A1 (en) 1998-03-06
HU227797B1 (en) 2012-03-28
AU4015897A (en) 1998-03-26
CZ61699A3 (en) 1999-06-16
CN1496980A (en) 2004-05-19
EP0931063B1 (en) 2006-10-18
DE59712752D1 (en) 2006-11-30
HUP9903741A3 (en) 2001-01-29
NO20030481L (en) 1999-03-04
KR100516321B1 (en) 2005-09-23
CN100376554C (en) 2008-03-26
DK0931063T5 (en) 2010-01-11
DK0931063T3 (en) 2007-02-19
HUP9903741A2 (en) 2000-04-28
NO314725B3 (en) 2009-03-09
ES2276433T3 (en) 2007-06-16
IL127798A (en) 2003-07-31
US6919344B2 (en) 2005-07-19
US20030207892A1 (en) 2003-11-06
PT931063E (en) 2007-02-28
NO314725B1 (en) 2003-05-12
JP3296437B2 (en) 2002-07-02
NO991071L (en) 1999-03-04

Similar Documents

Publication Publication Date Title
BR9712808B1 (en) unsubstituted indol-3-glyoxylamides, as well as the application, medicament and process for their preparation.
BR9804504B1 (en) substituted isoquinoline-3-carboxamides, process for their preparation and medicament.
BRPI9917862B1 (en) dihydropyrimidines, as well as a process for their preparation and application.
BR9913455B1 (en) MICROCAPLE FORMULATIONS AS WELL AS A PROCESS FOR PREPARING AND EMPLOYING THE SAME
BR9807685B1 (en) phthalazines, a pharmaceutical preparation comprising them, as well as use thereof.
BR9807502B1 (en) organic compounds, the process for their preparation, as well as their composition and application.
BR9911914B1 (en) Sulfur-substituted sulfonylaminocarboxylic acid n-arylamides, process for their preparation, as well as pharmaceutical preparations comprising them.
BR9713520B1 (en) cyclic imines, pesticide composition, process for the preparation and use of said cyclic imines and pesticide composition, as well as process for combating pests.
BR9802491B1 (en) multiple stable emulsion, and, process to form the same.
TR199601002A1 (en) 2-Oxo- and 2-thio-1, 2-dihydroquinolinyl-oxazolidinones.
BR9801181B1 (en) calcium-fortified foodstuff as well as a process for its preparation.
BR9914484B1 (en) MICROCAPLE FORMULATIONS AS WELL AS A PROCESS FOR PREPARING AND APPLYING THE SAME
BR9305625A (en) Hair fixing agent based on lignin or lignin derivatives, as well as dihydroxypropillignin
BR9808730B1 (en) 1,1,1,3,3-pentachlorobutane preparation process.
BR0008984B1 (en) appetizer type food and, process for preparing appetizer type food.
BR9714066B1 (en) process for the preparation of thiazole derivatives, as well as intermediates and processes for their preparation.
BR9913389B1 (en) preparation agents as well as preparation for their preparation.
BRPI9914571B8 (en) compound, process for its preparation, use thereof, as well as pharmaceutical composition.
BR0015675B1 (en) storage stable aerated gel composition and process for producing the same.
PT1053224E (en) BIPHENYLSULFONILCANAMIDE, PROCESS FOR THEIR PREPARATION AND ITS USE AS A DRUG
BR9705509B1 (en) 4-hydroxy-piperidine derivatives, process for their preparation as well as medicament containing them.
BR9916171B1 (en) molding masses, process for their preparation and use, as well as molded article.
BR9710537B1 (en) erythromycin derivatives, pharmaceutical compositions, as well as processes for preparing them.
PT1157020E (en) SUBSTITUTED 1,2,3,4,5,6-HEXA-HYDRO-2,6-METHANE-3-BENZAZOCIN-10-OIS PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINES
TR28525A (en) Master cylinder with increased safety.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/06/2009, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: BAXTER HEALTHCARE S.A. (CH) , BAXTER INTERNATIONAL

Free format text: TRANSFERIDO DE: ASTA MEDICA AKTIENGESELLSCHAFT

B25A Requested transfer of rights approved

Owner name: ZIOPHARM ONCOLOGY, INC. (US)

Free format text: TRANSFERIDO DE: BAXTER HEALTHCARE S.A. E BAXTER INTERNATIONAL INC.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.